Author:
Hentschel Leopold,Haering Charis
Publisher
Springer Science and Business Media LLC
Reference21 articles.
1. Arnold M, Rutherford MJ, Bardot A, Ferlay J, Andersson TML, Myklebust TÅ et al (2019) Progress in cancer survival, mortality, and incidence in seven high-income countries 1995–2014 (ICBP SURVMARK-2): a population-based study. Lancet Oncol 20(11):1493–1505
2. Robert Koch Institut (2016) Bericht zum Krebsgeschehen in Deutschland 2016
3. FDA (2009) Guidance for industry patient-reported outcome measures: use in medical product development to support labeling claims
4. Atkinson TM, Ryan SJ, Bennett AV, Stover AM, Saracino RM, Rogak LJ et al (2016) The association between clinician-based common terminology criteria for adverse events (CTCAE) and patient-reported outcomes (PRO): a systematic review. Support Care Cancer 24(8):3669–3676
5. Atkinson TM, Reeve BB, Dueck AC, Bennett AV, Mendoza TR, Rogak LJ, Basch E, Li Y (2018) Application of a Bayesian graded response model to characterize areas of disagreement between clinician and patient grading of symptomatic adverse events. J Patient Rep Outcomes 2(1):56. https://doi.org/10.1186/s41687-018-0086-x. PMID: 30515599; PMCID: PMC6279753